This site uses cookies to improve your experience. By viewing our content, you are accepting the use of cookies. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country we will assume you are from the United States. View our privacy policy and terms of use.

Remove 2016 Remove Clinical Development Remove Protein Production Remove Research
article thumbnail

Elasmogen announces a panel of novel, potent, anti-COVID-19 therapeutic candidates identified through collaboration with U.S. research partners

The Pharma Data

JANUARY 24, 2021

25, 2021 /PRNewswire/ — Elasmogen Ltd , the pioneering biopharmaceutical company leading the development of VNAR and soloMER biologics, today announces a significant breakthrough in the identification of next-generation protein-based drugs potentially capable of stopping COVID-19 infections. ABERDEEN, Scotland , Jan.

Research 52
Research Virus Medical Schools Government 52
article thumbnail

Beyond Steel Tanks

Codon

MARCH 24, 2024

After decades of research, their GLP-1 obesity drugs appear to really work. A 2019 report from RethinkX, an independent research group, states that the “cost to produce a single molecule using [precision fermentation] has fallen from $1 million per kilogram in 2000, to about $100 today.” Read this essay on our website.

Engineering 85
Engineering Vaccine Production RNA 85
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 

Stay Connected

Join 15,000+ Insiders by signing up for our newsletter

About
About
Editions
Editions
Topics
Powered by Aggregage | Terms and Conditions | Your California Rights and Privacy Policy
© Aggregage 2024